MCW NCTN Lead Academic Participating Site

MCW NCTN 主导学术参与网站

• 批准号: 10371071
• 负责人: William H Bradley
• 金额: $ 59.5万
• 依托单位: MEDICAL COLLEGE OF WISCONSIN
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-07 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10371071
• 关键词: Address; Adult; American College of Radiology Imaging Network; Biometry; Blood; Bone Marrow Transplantation; Cancer Center; Cancer Patient; Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Network; Conduct Clinical Trials; Development; Discipline; Disease; Eastern Cooperative Oncology Group; Ensure; Faculty; Funding; Grant; Growth; Health; Hematology; Hematopoietic Stem Cell Transplantation; Human Resources; Individual; Information Technology; Informed Consent; Infrastructure; Institutes; Intervention; Investments; Lead; Leadership; Logistics; Malignant Neoplasms; Master of Science; Medical Oncology; Mentors; Methodology; Methods; Mission; Multi-Institutional Clinical Trial; Multicenter Trials; National Cancer Institute; National Clinical Trials Network; Oncology; Outcome; Phase; Physician Executives; Play; Positioning Attribute; Process; Publications; Radiation Oncology; Radiation therapy; Recording of previous events; Research; Research Personnel; Research Support; Resources; Role; Scientist; Site; Solid; Southwest Oncology Group; Standardization; Statistical Methods; Surgical Oncology; Technology; Time; Training; Translational Research; Wisconsin; Work; Writing; cancer care; cancer clinical trial; cancer diagnosis; cancer imaging; cancer prevention; cancer therapy; empowered; experience; interdisciplinary approach; medical schools; member; next generation; operation; pre-clinical; programs; recruit; senior faculty; skills training; treatment center; trial design

PROJECT SUMMARY An effective National Cancer Clinical Trials (NCTN) must be led by centers with commitment to, and expertise in, the collaborative clinical trials process. The Medical College of Wisconsin (MCW) has a 45-year tradition of such commitment as demonstrated by scientific leadership in development and conduct of clinical trials in association with NRG Oncology, Alliance for Clinical Trials in Oncology, ECOG-ACRIN, and SWOG, in addition to leadership and substantial accrual to other National Cancer Institute (NCI)-funded trials networks. In the past 5 years, the Froedtert & MCW Cancer Center (FMCWCC) has gone through transformative growth and is well- positioned to exert sustained meaningful influence as a Lead Academic Participating Site (LAPS). FMCWCC has a leadership team has diverse experience, a proven track record, and an effective infrastructure that will continue to provide scientific leadership in the development of trials, contribute to timely accrual and completion of trials, and mentor the next generation of investigators. FMCWCC will support the mission and the operation of the NCTN by 1) providing leadership in developing important and successful multicenter trials that address critical issues in cancer diagnosis and treatment utilizing MCW expertise in pre-clinical, translational, and early phase and advanced phase clinical research; 2) providing robust accrual to NCTN trials with wide participation by all MCW cancer disciplines; 3) Developing the next generation of NCTN clinical scientists through mentoring programs and advanced methods training. MCW has played a scientific leadership role in national adult clinical trials programs for many decades and has made substantial recent investments in recruitment and infrastructure to vigorously grow its clinical trial program. This comes with an explicit commitment to grow NCTN activities by: (i) empowering the NCTN leadership in our Cancer Center infrastructure; (ii) engaging faculty with extensive expertise in both the cooperative groups and other non-profit trials networks to develop, activate and accrue to NCTN trials; (iii) centralizing and expanding clinical research support activities to further increase capacity, efficiency and accrual; and (iv) mentoring the next generation of investigators.

项目摘要 有效的国家癌症临床试验（NCTN）必须由对专业知识的承诺和专业知识的中心领导 在协作临床试验过程中。威斯康星州医学院（MCW）具有45年的传统 科学领导力在发展和进行临床试验中的科学领导证明的承诺 与NRG肿瘤学，肿瘤学临床试验联盟，ECOG-ACRIN和SWOG的关联，此外 为其他国家癌症研究所（NCI）资助的试验网络提供领导力和实质性应计。在过去 5年，Froedtert＆McW癌症中心（FMCWCC）经历了变革性的增长，并且非常好 作为领导学术参与地点（LAPS）的持续有意义的影响力。 FMCWCC 有一个领导团队拥有多样的经验，可靠的往绩以及有效的基础设施 继续在开发试验方面提供科学领导，及时累积和完成 试验，并指导下一代研究人员。 FMCWCC将支持任务和操作 1）在开发重要和成功的多中心试验方面提供领导才能 癌症诊断和治疗中使用MCW专业知识的癌症诊断和治疗问题的关键问题 阶段和晚期临床研究； 2）为NCTN试验提供强大的应计参与度 所有MCW癌症学科； 3）通过指导开发下一代NCTN临床科学家 程序和高级方法培训。 MCW在国家成人临床中发挥了科学领导作用 经过数十年的试验计划，并在招聘和基础设施上进行了大量投资 大力发展其临床试验计划。这带有明确的承诺，致力于发展NCTN活动： （i）在我们的癌症中心基础设施中赋予NCTN领导力； （ii）吸引教师广泛 在合作团体和其他非营利性试验网络中的专业知识，以开发，激活和累积 NCTN试验； （iii）集中和扩大临床研究支持活动，以进一步增加容量， 效率和应计； （iv）指导下一代研究人员。